Long non-coding RNA Lucat1 is a poor prognostic factor and demonstrates malignant biological behavior in clear cell renal cell carcinoma
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1948 views | HTML 2004 views | ?
Haibing Xiao1,2, Lin Bao2, Wen Xiao2, Hailong Ruan2, Zhengshuai Song2, Yan Qu1, Ke Chen2, Xiaoping Zhang2 and Hongmei Yang1
1Department of Pathogenic Biology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Hongmei Yang, email: [email protected]
Xiaoping Zhang, email: [email protected]
Keywords: Lucat1; EZH2; p57
Received: May 02, 2017 Accepted: July 29, 2017 Published: September 23, 2017
Background: Many long intergenic noncoding RNAs (lincRNAs) are encoded in the human genome. However, their biological functions, molecular mechanisms and prognostic values associated with clear cell renal cell carcinoma (ccRCC) have yet to be elucidated.
Methods: We screened the lncRNAs’ profile in ccRCC from The Cancer Genome Atlas (TCGA) database, and selected Lucat1 for further study. MTS, colony formation assay and transwell assay were performed to examine the effect of Lucat1 on proliferation and metastasis of ccRCC. The Chip and Rip assay was performed to verify that Lucat1 can bind to polycomb PRC2 complex and suppress p57 expression.
Results: In this study, we found that lncRNA Lucat1 expression was significantly up regulated in tumor tissues compared to matched adjacent non-tumor tissues. The Lucat1 expression level was also associated with grade, the clinical pathological stage and the survival time. Functional assays showed that Lucat1 can promote renal cancer cell proliferation in vitro and in vivo. Further analysis showed that Lucat1 can bind to polycomb PRC2 complex and suppress p57 expression.
Conclusions: Taken together, our results suggest that Lucat1, as a regulator of proliferation, may serve as a candidate prognostic biomarker and target for novel therapies in human ccRCC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.